论文部分内容阅读
目的探讨血清胸苷激酶1(STK1)用于筛查早期泌尿系统恶性肿瘤中的价值。方法利用免疫印记增强化学发光法检测恶性肿瘤患者组、良性疾病组、正常对照组的血清胸苷激酶浓度及阳性率。结果发现前列腺癌组、膀胱癌组、肾癌组与正常对照组间STK1水平有明显差异(P<0.05),与泌尿系统良性疾病组STK1水平也存在明显差异(P<0.05)。结论采用血清胸苷激酶1,在筛查泌尿系统早期恶性肿瘤中有一定的临床价值。
Objective To investigate the value of serum thymidine kinase 1 (STK1) in the screening of early urological malignancies. Methods Immunostaining enhanced chemiluminescence was used to detect serum thymidine kinase concentration and positive rate in malignant tumor patients, benign disease patients and normal controls. The results showed that the level of STK1 in prostate cancer, bladder cancer, kidney cancer and normal controls were significantly different (P <0.05), but also significantly different from that in benign diseases of urinary tract (P <0.05). Conclusion Serum thymidine kinase 1 has certain clinical value in the screening of early malignant tumors of the urinary system.